search
Back to results

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

Primary Purpose

Depression, Anxiety

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
IDgenetix Neuropsychiatric Test Panel
Sponsored by
AltheaDx
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Depression focused on measuring PGx, pharmacogenetics, depression, anxiety, Neuropsychiatric diseases, IDgenetix, AltheaDx

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female subjects between the ages of 18 and 80
  • Experiencing or showing evidence of a neuropsychiatric disorder (depression, anxiety, attention deficit hyperactivity disorder and psychosis) as determined by a qualified clinician
  • Subjects new to the medical provider
  • Willing and able to comply with study procedures
  • Able to provide written informed consent

Exclusion Criteria:

  • Unwilling or unable to provide written informed consent and to comply with study procedures
  • Any subject for whom providing a buccal swab sample would be contraindicated or not possible
  • Subject with a history of chronic renal dysfunction, Chronic Kidney Disease (Stage 4 or 5)
  • Abnormal hepatic function within the last 2 years (INR >1.2 not attributable to anticoagulant medications, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5x normal, or suspected cirrhosis
  • History of malabsorption (short gut syndrome)
  • Any gastric or small bowel surgery less than 3 months prior to study enrollment
  • Subject is being treated with intravenous medication

Sites / Locations

  • Carolina Partners in Mental HealthCare

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

IDgenetix Neuropsychiatric Test Panel Intervention

control

Arm Description

The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.

The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.

Outcomes

Primary Outcome Measures

Comparison of change in neuropsychiatric state between the two treatment arms measured by Neuropsychiatric Questionnaire (NPQ)
Neuropsychiatric Questionnaire (NPQ) score change comparison between the two treatment arms over a 4-month period.
Comparison of change in responsiveness between the two treatment arms measured by Symbol Digit Coding (SDC) test
Symbol Digit Coding (SDC) test score change comparison between the two treatment arms over a 4-month period.

Secondary Outcome Measures

Comparison of hospital utilization between the two treatment arms as measured by hospital admission and re-admission rates
Comparison of hospital utilization, as measured by hospital admission and re-admission rates, between the two treatment arms over a 4-month period.
Comparison of adverse drug events between the two treatment arms over a 4-month period
Comparison of adverse drug events between the two treatment arms over a 4-month period

Full Information

First Posted
April 1, 2015
Last Updated
December 28, 2015
Sponsor
AltheaDx
Collaborators
Carolina Partners in Mental Healthcare
search

1. Study Identification

Unique Protocol Identification Number
NCT02411123
Brief Title
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
Official Title
Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AltheaDx
Collaborators
Carolina Partners in Mental Healthcare

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their treatment. This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug events, hospitalization rates, hospital length of stay, emergency room visits, disability, death or other serious drug side effects.
Detailed Description
Anti-depressant and anti-anxiety medications are still administered by a trial and error method, which results in a substantial number of patients suffering from either a lack of benefit from drug therapy or severe side effects. Approximately 40% of all anti-depressant and anti-anxiety medications prescribed are ineffective, and patients who need to be on medication often discontinue taking their medications, which can have potentially dangerous consequences. Clinical features often fail to predict the drug response and tolerability of a patient to a prescription medication. Genetics can help guide therapeutic decisions for patients exhibiting neuropsychiatric disorders and improve patient outcomes by maximizing drug efficacy and minimizing the risk of adverse events. Genetics and drug interactions can alter both the pharmacokinetics and pharmacodynamics of a multitude of drug compounds and in turn influence both the safety and efficacy of selected therapeutic regimens. Pharmacogenetic-guided therapy selection using the IDgenetix Neuropsychiatric Test Panel can enhance patient response and tolerability by facilitating the selection of the most appropriate medication at the most effective dose in the shortest possible time. In this prospective, randomized, single-blind study, new patients presenting to the clinical site with evidence of depression or anxiety as determined by a qualified clinician will be invited to participate. Study participants will be randomized to one of two groups with respect to the IDgenetix Neuropsychiatric Test Panel result: group with testing results revealed to the medical provider prior to treatment selection (Experimental Group) or group without testing results prior to treatment selection (Control Group). Participant outcomes will be measured at baseline and throughout the 4-month duration of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Anxiety
Keywords
PGx, pharmacogenetics, depression, anxiety, Neuropsychiatric diseases, IDgenetix, AltheaDx

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
220 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IDgenetix Neuropsychiatric Test Panel Intervention
Arm Type
Experimental
Arm Description
The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
Arm Title
control
Arm Type
No Intervention
Arm Description
The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
Intervention Type
Genetic
Intervention Name(s)
IDgenetix Neuropsychiatric Test Panel
Other Intervention Name(s)
PGx Testing
Intervention Description
The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Primary Outcome Measure Information:
Title
Comparison of change in neuropsychiatric state between the two treatment arms measured by Neuropsychiatric Questionnaire (NPQ)
Description
Neuropsychiatric Questionnaire (NPQ) score change comparison between the two treatment arms over a 4-month period.
Time Frame
4 months
Title
Comparison of change in responsiveness between the two treatment arms measured by Symbol Digit Coding (SDC) test
Description
Symbol Digit Coding (SDC) test score change comparison between the two treatment arms over a 4-month period.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Comparison of hospital utilization between the two treatment arms as measured by hospital admission and re-admission rates
Description
Comparison of hospital utilization, as measured by hospital admission and re-admission rates, between the two treatment arms over a 4-month period.
Time Frame
4 months
Title
Comparison of adverse drug events between the two treatment arms over a 4-month period
Description
Comparison of adverse drug events between the two treatment arms over a 4-month period
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects between the ages of 18 and 80 Experiencing or showing evidence of a neuropsychiatric disorder (depression, anxiety, attention deficit hyperactivity disorder and psychosis) as determined by a qualified clinician Subjects new to the medical provider Willing and able to comply with study procedures Able to provide written informed consent Exclusion Criteria: Unwilling or unable to provide written informed consent and to comply with study procedures Any subject for whom providing a buccal swab sample would be contraindicated or not possible Subject with a history of chronic renal dysfunction, Chronic Kidney Disease (Stage 4 or 5) Abnormal hepatic function within the last 2 years (INR >1.2 not attributable to anticoagulant medications, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5x normal, or suspected cirrhosis History of malabsorption (short gut syndrome) Any gastric or small bowel surgery less than 3 months prior to study enrollment Subject is being treated with intravenous medication
Facility Information:
Facility Name
Carolina Partners in Mental HealthCare
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
14512135
Citation
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003 Aug;25(8):2289-304. doi: 10.1016/s0149-2918(03)80220-5.
Results Reference
background
PubMed Identifier
21687501
Citation
Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A. Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6. doi: 10.3389/fphar.2011.00006. eCollection 2011.
Results Reference
background
PubMed Identifier
20373668
Citation
Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci. 2010;12(1):69-76. doi: 10.31887/DCNS.2010.12.1/dmrazek.
Results Reference
background
PubMed Identifier
17146470
Citation
Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007 Mar;12(3):247-57. doi: 10.1038/sj.mp.4001926. Epub 2006 Dec 5.
Results Reference
background
PubMed Identifier
28314093
Citation
Olson MC, Maciel A, Gariepy JF, Cullors A, Saldivar JS, Taylor D, Centeno J, Garces JA, Vaishnavi S. Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. Prim Care Companion CNS Disord. 2017 Mar 16;19(2). doi: 10.4088/PCC.16m02036.
Results Reference
derived

Learn more about this trial

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

We'll reach out to this number within 24 hrs